Drug Science, Policy and Law aims to be the definitive source of evidence-based information and comment for academics, scientists, policymakers, frontline workers and the general public on drugs and related issues.
A peer-reviewed journal of science, policy and law relating to drugs, Drug Science, Policy and Law is international in scope and grounded in a rigorous evidence base making it essential reading for all those in the field and related disciplines.
In particular, the following topics are covered:
Those relating to drug science, both from hard science – addiction science, chemistry, psychopharmacology, psychiatry, psychology, forensic toxicology, behavioural neuroscience – and from social science and other related fields – criminology, law, policy.
|Valerie Curran||University College London, UK|
|Michael Farrell||University of New South Wales, Australia|
|Rudi Fortson||Queen Mary University of London, UK|
|João Goulão||SICAD, Portugal|
|Mohamad Hussain Bin Habil||University of Malaya, Malaysia|
|Wayne Hall||University of Queensland, Australia|
|Martin Jelsma||Transnational Institute, Netherlands|
|Evgeny Krupitsky||Bekhterev St. Petersburg Research Psychoneurological Institute, Russia|
|Fiona Measham||Durham University, UK|
|Charles O'Brien||University of Pennsylvania, USA|
|Rajat Ray||All India Institute of Medical Sciences, India|
|Peter Reuter||University of Maryland, USA|
|Alison Ritter||University of New South Wales, Australia|
|Douglas Sellman||University of Otago, New Zealand|
|Rachel Tyndale||University of Toronto, Canada|
|Wim van den Brink||Academic Medical Center, Netherlands|
This Journal is a member of the Committee on Publication Ethics
This Journal recommends that authors follow the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals formulated by the International Committee of Medical Journal Editors (ICMJE).
Please read the guidelines below then email email@example.com to submit your manuscript. Please note that manuscripts not conforming to these guidelines may be returned.
Only manuscripts of sufficient quality that meet the aims and scope of Drug Science, Policy and Law will be reviewed.
There are no fees payable to submit or publish in this journal.
As part of the submission process you will be required to warrant that you are submitting your original work, that you have the rights in the work, that you are submitting the work for first publication in the Journal and that it is not being considered for publication elsewhere and has not already been published elsewhere, and that you have obtained and can supply all necessary permissions for the reproduction of any copyright works not owned by you.
- What do we publish?
1.1 Aims & Scope
1.2 Article types
1.3 Writing your paper
- Editorial policies
2.1 Peer review policy
2.5 Declaration of conflicting interests
2.6 Research ethics and patient consent
2.7 Clinical trials
2.8 Reporting guidelines
- Publishing policies
3.1 Publication ethics
3.2 Contributor's publishing agreement
3.3 Open access and author archiving
- Preparing your manuscript
4.2 Artwork, figures and other graphics
4.3 Supplementary material
4.4 Reference style
4.5 English language editing services
- Submitting your manuscript
5.2 Information required for completing your submission
- On acceptance and publication
6.1 SAGE Production
6.2 Online First publication
6.3 Access to your published article
6.4 Promoting your article
- Further information
Before submitting your manuscript to Drug Science, Policy and Law, please ensure you have read the Aims & Scope.
Drug Science, Policy and Law is a peer-reviewed journal publishing original research and review articles on all aspects of drug science, policy, and law. The journal considers the following kinds of article for publication:
1. Research Reports: describing new experimental findings
Short reports requiring rapid dissemination
2. Review Articles: the Editors wish to encourage the following types of review, but request that authors contact them in advance:
General reviews that provide a view of an area of drug science, policy and/or law;
perspectives - brief overviews, including references, that address important new areas of general interest;
critiques - focused and provocative reviews that are followed by a number of invited commentaries, with a concluding reply from the main author
Reports and articles should preferably be on a currently relevant issue, targeting either the research community, current affairs, public interests, or all of these. They should be based on a succinct and balanced summary of existing research on the issue.
3. Letters to the Editors: readers' letters should address issues raised by published articles or should report significant new findings that merit rapid dissemination. The decision to publish is made by the Editors, in order to ensure a timely appearance in print.
4. Word length: though there are no strict guidelines, f ull papers are generally restricted to a maximum of 4,000 words, including all elements (title page, abstract, notes, references, tables, biographical statement, etc.). We are reluctant to burden our referees with very long manuscripts. Authors who suspect that their articles will have to be cut anyway should make the required deletions before submitting.
Writing Style: Drug Science, Policy and Law is produced for the public and professionals as well as academics so we ask that papers are written to be intelligible to the intelligent layperson.
The SAGE Author Gateway has some general advice and on how to get published, plus links to further resources.
1.3.1 Make your article discoverable
When writing up your paper, think about how you can make it discoverable. The title, keywords and abstract are key to ensuring readers find your article through search engines such as Google. For information and guidance on how best to title your article, write your abstract and select your keywords, have a look at this page on the Gateway: How to Help Readers Find Your Article Online.
Drug Science, Policy and Law operates a strictly anonymous peer review process in which the reviewer’s name is withheld from the author . The reviewer may at their own discretion opt to reveal their name to the author in their review . Each manuscript is reviewed by at least two referees. All manuscripts are reviewed as rapidly as possible, and an editorial decision is generally reached within 4-6 weeks of submission.
Papers should only be submitted for consideration once consent is given by all contributing authors. Those submitting papers should carefully check that all those whose work contributed to the paper are acknowledged as contributing authors.
The list of authors should include all those who can legitimately claim authorship. This is all those who:
(i) Made a substantial contribution to the concept or design of the work; or acquisition, analysis or interpretation of data,
(ii) Drafted the article or revised it critically for important intellectual content,
(iii) Approved the version to be published,
(iv) Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content.
Authors should meet the conditions of all of the points above. When a large, multicentre group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript. These individuals should fully meet the criteria for authorship.
Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship, although all contributors who do not meet the criteria for authorship should be listed in the Acknowledgments section. Please refer to the International Committee of Medical Journal Editors (ICMJE) authorship guidelines for more information on authorship.
All contributors who do not meet the criteria for authorship should be listed in an Acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, or a department chair who provided only general support.
Any acknowledgements should appear first at the end of your article prior to your Declaration of Conflicting Interests (if applicable), any notes and your References.
2.3.1 Writing assistance
Individuals who provided writing assistance, e.g. from a specialist communications company, do not qualify as authors and so should be included in the Acknowledgements section. Authors must disclose any writing assistance – including the individual’s name, company and level of input – and identify the entity that paid for this assistance. It is not necessary to disclose use of language polishing services.
Drug Science, Policy and Law requires all authors to acknowledge their funding in a consistent fashion under a separate heading. Please visit the Funding Acknowledgements page on the SAGE Journal Author Gateway to confirm the format of the acknowledgment text in the event of funding, or state that: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
It is the policy of Drug Science, Policy and Law to require a declaration of conflicting interests from all authors enabling a statement to be carried within the paginated pages of all published articles.
Please ensure that a ‘Declaration of Conflicting Interests’ statement is included at the end of your manuscript, after any acknowledgements and prior to the references. If no conflict exists, please state that ‘The Author(s) declare(s) that there is no conflict of interest’. For guidance on conflict of interest statements, please see the ICMJE recommendations here.
Medical research involving human subjects must be conducted according to the World Medical Association Declaration of Helsinki.
Submitted manuscripts should conform to the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, and all papers reporting animal and/or human studies must state in the methods section that the relevant Ethics Committee or Institutional Review Board provided (or waived) approval. Please ensure that you have provided the full name and institution of the review committee, in addition to the approval number.
For research articles, authors are also required to state in the methods section whether participants provided informed consent and whether the consent was written or verbal.
Information on informed consent to report individual cases or case series should be included in the manuscript text. A statement is required regarding whether written informed consent for patient information and images to be published was provided by the patient(s) or a legally authorized representative.
Please also refer to the ICMJE Recommendations for the Protection of Research Participants.
Drug Science, Policy and Law conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract.
The relevant EQUATOR Network reporting guidelines should be followed depending on the type of study. For example, all randomized controlled trials submitted for publication should include a completed CONSORT flow chart as a cited figure and the completed CONSORT checklist should be uploaded with your submission as a supplementary file. Systematic reviews and meta-analyses should include the completed PRISMA flow chart as a cited figure and the completed PRISMA checklist should be uploaded with your submission as a supplementary file. The EQUATOR wizard can help you identify the appropriate guideline.
Other resources can be found at NLM’s Research Reporting Guidelines and Initiatives
SAGE acknowledges the importance of research data availability as an integral part of the research and verification process for academic journal articles.
Drug Science, Policy and Law requests all authors submitting any primary data used in their research articles alongside their article submissions to be published in the online version of the journal, or provide detailed information in their articles on how the data can be obtained. This information should include links to third-party data repositories or detailed contact information for third-party data sources. Data available only on an author-maintained website will need to be loaded onto either the journal’s platform or a third-party platform to ensure continuing accessibility.
Examples of data types include but are not limited to statistical data files, replication code, text files, audio files, images, videos, appendices, and additional charts and graphs necessary to understand the original research. The editor may consider limited embargoes on proprietary data. The editors can also grant exceptions for data that cannot legally or ethically be released. All data submitted should comply with Institutional or Ethical Review Board requirements and applicable government regulations. For further information, please contact the editorial office at firstname.lastname@example.org.
SAGE is committed to upholding the integrity of the academic record. We encourage authors to refer to the Committee on Publication Ethics’ International Standards for Authors and view the Publication Ethics page on the SAGE Author Gateway.
Drug Science, Policy and Law and SAGE take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. We seek to protect the rights of our authors and we always investigate claims of plagiarism or misuse of published articles. Equally, we seek to protect the reputation of the journal against malpractice. Submitted articles may be checked with duplication-checking software. Where an article, for example, is found to have plagiarised other work or included third-party copyright material without permission or with insufficient acknowledgement, or where the authorship of the article is contested, we reserve the right to take action including, but not limited to: publishing an erratum or corrigendum (correction); retracting the article; taking up the matter with the head of department or dean of the author's institution and/or relevant academic bodies or societies; or taking appropriate legal action.
3.1.2 Prior publication
If material has been previously published it is not generally acceptable for publication in a SAGE journal. However, there are certain circumstances where previously published material can be considered for publication. Please refer to the guidance on the SAGE Author Gateway or if in doubt, contact the Editor at the address given below.
Before publication, SAGE requires the author as the rights holder to sign a Journal Contributor’s Publishing Agreement. SAGE’s Journal Contributor’s Publishing Agreement is an exclusive licence agreement which means that the author retains copyright in the work but grants SAGE the sole and exclusive right and licence to publish for the full legal term of copyright. Exceptions may exist where an assignment of copyright is required or preferred by a proprietor other than SAGE. In this case copyright in the work will be assigned from the author to the society. For more information please visit the SAGE Author Gateway.
Drug Science, Policy and Law offers optional open access publishing via the SAGE Choice programme. For more information please visit the SAGE Choice website. For information on funding body compliance, and depositing your article in repositories, please visit SAGE Publishing Policies on our Journal Author Gateway.
The preferred format for your manuscript is Word. LaTeX files are also accepted. Word and (La)Tex templates are available on the Manuscript Submission Guidelines page of our Author Gateway.
For guidance on the preparation of illustrations, pictures and graphs in electronic format, please visit SAGE’s Manuscript Submission Guidelines.
Figures supplied in colour will appear in colour online and in the print issue. There is no charge for reproducing figures in colour in the printed version.
This journal is able to host additional materials online (e.g. datasets, podcasts, videos, images etc) alongside the full-text of the article. For more information please refer to our guidelines on submitting supplementary files.
Drug Science, Policy and Law adheres to the SAGE Harvard reference style. View the SAGE Harvard guidelines to ensure your manuscript conforms to this reference style.
Authors seeking assistance with English language editing, translation, or figure and manuscript formatting to fit the journal’s specifications should consider using SAGE Language Services. Visit SAGE Language Services on our Journal Author Gateway for further information.
Manuscripts and illustrations should be submitted to the Editorial Manager by e-mail attachment: Dr Pallab Seth at email@example.com
Please also ensure that you have obtained any necessary permission from copyright holders for reproducing any illustrations, tables, figures or lengthy quotations previously published elsewhere. For further information including guidance on fair dealing for criticism and review, please see the Copyright and Permissions page on the SAGE Author Gateway.
Your SAGE Production Editor will keep you informed as to your article’s progress throughout the production process. Proofs will be sent by PDF to the corresponding author and should be returned promptly. Authors are reminded to check their proofs carefully to confirm that all author information, including names, affiliations, sequence and contact details are correct, and that Funding and Conflict of Interest statements, if any, are accurate. Please note that if there are any changes to the author list at this stage all authors will be required to complete and sign a form authorising the change.
Online First allows final articles (completed and approved articles awaiting assignment to a future issue) to be published online prior to their inclusion in a journal issue, which significantly reduces the lead time between submission and publication. Visit the SAGE Journals help page for more details, including how to cite Online First articles.
SAGE provides authors with online access to their final article.
Publication is not the end of the process! You can help disseminate your paper and ensure it is as widely read and cited as possible. The SAGE Author Gateway has numerous resources to help you promote your work. Visit the Promote Your Article page on the Gateway for tips and advice. In addition, SAGE is partnered with Kudos, a free service that allows authors to explain, enrich, share, and measure the impact of their article. Find out how to maximise your article’s impact with Kudos.
Any correspondence, queries or additional requests for information on the manuscript submission process should be sent to the Drug Science, Policy and Law editorial office as follows: